Clinical Trial Update: A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase [Phase 1]

View source ↗

Summary

Phase 1 dose-escalation/expansion trial of LDK378 in ALK-altered tumors has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tumors Characterized By Genetic Abnormalities of Alk

Drugs mentioned

• LDK378 (Alectinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Tumors Characterized by Genetic Abnormalities of ALK | Phase 1 | Status: COMPLETED | Results posted: 2014-08-11